Nicholas Bodor

Nicholas Bodor, Ph.D.

Graduate Research Professor Emeritus

Department: Pharmaceutics
Business Email: bodor@cop.ufl.edu

About Nicholas Bodor

Bodor received his B.S./M.S. degree in Organic Chemistry in 1959 at Bolyai University in Transylvania, and his Ph.D. degree in 1965 from the University of Babes-Bolyai, Cluj and the Romanian National Academy of Sciences. He was a Group Leader at the Pharmacochemical Research Institute in Romania until 1968, when he received a R. A. Welch Fellowship at the University of Texas in Austin. In 1972 he became a Senior Research Scientist at ALZA Laboratories in Lawrence, Kansas, which later became INTERx Research Corporation, where he was Director of Research, as well as an Adjunct Professor at the University of Kansas until 1978.

Bodor joined the University of Florida in Gainesville in 1979 as Professor and Chairman of the Medicinal Chemistry Department. He was promoted to Graduate Research Professor of the university in 1983. He is the Executive Director of the Center for Drug Discovery in the College of Pharmacy. He also holds appointments as Affiliate Graduate Research Professor in the Department of Chemistry in the College of Liberal Arts and the Department of Ophthalmology in the College of Medicine at the University. During his tenure at the University of Florida, he has supervised the training of more than 50 doctoral students and over 100 postdoctoral level research associates and fellows. In February 2000, he took a leave of absence from his academic posts at UF to accept a position as Senior Vice President of Basic Research and Drug Discovery at the IVAX Corporation. Bodor served as Chief Scientific Officer of the IVAX Corporation, Managing Director of the IVAX Drug Research Institute, Budapest, Hungary, as well as President of the IVAX Research Institute until October 2005, when he returned to the University of Florida as Graduate Research Professor and Executive Director of the Center for Drug Discovery.

Inducted into the American chemical Society’s Hall of Fame, Division of Medicinal Chemistry.

He is an elected Fellow of the Academy of Pharmaceutical Sciences, the American Association of Pharmaceutical Scientists, the American Association for the Advancement of Science, and American College of Clinical Pharmacology. He is also an Honorary Member of the Hungarian Chemical Society and the Panhellenic Society of Pharmacists. Among other honors, Dr. Bodor has been named “The 1984 Florida Scientist of the Year” and received the first AAPS Research Achievement Award in Medicinal and Natural Product Chemistry in 1988, as well as the APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry in 1989. In 1989 he also received an honorary Doctor of Science degree from the Technical University of Budapest, and then was awarded the Doctor Honoris Causa degree from the Medical University of Debrecen in 1990. In 1994 he was named the first recipient of the Nagai Foundation Tokyo International Fellowship. In 1995 he was elected to the Hungarian National Academy of Sciences. He was named by the American Chemical Society as the 1996 recipient of the Leo Friend Award in recognition of his article entitled, “Design of Biologically Safer Chemicals,” published in Chemtech, October 1995. He is the first College of Pharmacy faculty member to receive a Professorial Excellence Award, given by the University of Florida in 1996. The AACP selected Dr. Bodor as the recipient of the 1997 Volwiler Research Achievement Award. In April 2000, Bodor was named the V. Ravi Chandran Professor in Drug Design and Targeting of the UF College of Pharmacy, the first recipient of this endowed professorship. In February 2002, he was elected a Fellow of the World Innovation Foundation. In 2004, Ferenc Madl, President of Hungary, awarded Bodor the Gold Cross of Merit of the Hungarian Republic. An honorary Doctor of Science degree was conferred upon Bodor by the University of Florida in 2005. In 2007, the American Association of Pharmaceutical Scientists awarded Bodor with a Distinguished Pharmaceutical Scientist Award.

Research Profile

Bodor’s main research interests include design of drugs with improved therapeutic index, design of new chemical delivery systems, computer-assisted drug design, drug transport and metabolism, and theoretical and mechanistic organic chemistry. He has published more than 500 research articles, holds more than 180 patents, and is on the editorial boards of several international scientific journals. Bodor is the founder and organizer of a biennial series of symposia entitled, The Retrometabolism Based Drug Design and Targeting Conference, which is dedicated to the study of the drug optimization strategies that he has pioneered. The soft steroid Loteprednol Etabonate, he designed, is on the market in the U.S. and other countries. Other drugs he has designed using the retrometabolic concepts are in advanced clinical development.

Publications

2020
Modulation of expression/function of intestinal P-glycoprotein under disease states.
Expert opinion on drug metabolism & toxicology. 16(1):59-78 [DOI] 10.1080/17425255.2020.1701653. [PMID] 31821048.
2019
Identification of Major Esterase Involved in Hydrolysis of Soft Anticholinergic (2R3’R-SGM) Designed From Glycopyrrolate in Human and Rat Tissues.
Journal of pharmaceutical sciences. 108(8):2791-2797 [DOI] 10.1016/j.xphs.2019.03.030. [PMID] 30954525.
2017
Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids.
The Journal of pharmacy and pharmacology. 69(12):1745-1753 [DOI] 10.1111/jphp.12819. [PMID] 28980320.
2017
Identification of esterase involved in the metabolism of two corticosteroid soft drugs.
Biochemical pharmacology. 127:82-89 [DOI] 10.1016/j.bcp.2016.12.010. [PMID] 28017774.
2016
Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster.
Journal of pharmaceutical sciences. 105(9):2589-2600 [DOI] 10.1016/j.xphs.2016.04.007. [PMID] 27209462.
2016
Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin.
Journal of pharmaceutical sciences. 105(9):2873-2878 [DOI] 10.1016/j.xphs.2016.03.028. [PMID] 27179671.
2012
The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
Die Pharmazie. 67(5):406-10 [PMID] 22764572.
View on: PubMed
2010
Feasibility of Localized Immunosuppression: 1. Exploratory Studies With Glucocorticoids in a Biohybrid Device Designed for Cell Transplantation
Die Pharmazie. 65(6):421-428 [DOI] 10.1691/ph.2010.0525R. [PMID] 20614690.
2010
Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Die Pharmazie. 65(6):429-35 [PMID] 20614691.
View on: PubMed
2010
Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.
Die Pharmazie. 65(6):412-6 [PMID] 20614688.
View on: PubMed
2010
Recent advances in retrometabolic drug design (RMDD) and development.
Die Pharmazie. 65(6):395-403 [PMID] 20614685.
View on: PubMed
2008
Soft Corticosteroids for Local Immunosuppression: Exploring the Possibility for the Use of Loteprednol Etabonate for Islet Transplantation
Die Pharmazie. 63(3):226-232 [DOI] 10.1691/ph.2008.7774. [PMID] 18444512.
2008
Selective Reduction of Trigonellyl Group To the Corresponding Dihydropyridine in the Presence of Disulfide Group
Bulletin of the Korean Chemical Society. 29:479-482
2008
Stereoisomers of N-substituted soft anticholinergics and their zwitterionic metabolite based on glycopyrrolate–syntheses and pharmacological evaluations.
Die Pharmazie. 63(3):200-9 [PMID] 18444508.
View on: PubMed
2008
Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
The Journal of pharmacy and pharmacology. 60(3):291-7 [DOI] 10.1211/jpp.60.3.0003. [PMID] 18284808.
2008
Retrometabolic Drug Design: Principles and Recent Developments
Pure and Applied Chemistry. 80(8):1669-1682 [DOI] 10.1351/pac200880081669.
2007
Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side-chains.
The Journal of pharmacy and pharmacology. 59(8):1065-76 [PMID] 17725848.
View on: PubMed
2006
Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.
Current pharmaceutical design. 12(25):3241-60 [PMID] 17020532.
View on: PubMed
2006
Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) model.
Journal of medicinal chemistry. 49(3):883-91 [PMID] 16451054.
View on: PubMed
2005
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.
The AAPS journal. 7(4):E820-33 [PMID] 16594634.
View on: PubMed
2005
Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics.
Pharmaceutical research. 22(12):2035-44 [PMID] 16170596.
View on: PubMed
2005
Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Journal of pharmacokinetics and pharmacodynamics. 32(3-4):377-400 [PMID] 16320099.
View on: PubMed
2004
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Molecular biotechnology. 26(2):123-32 [PMID] 14764938.
View on: PubMed
2004
New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox.
Pharmacology, biochemistry, and behavior. 77(3):423-9 [PMID] 15006452.
View on: PubMed
2003
Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics.
Pharmaceutical research. 20(10):1681-9 [PMID] 14620526.
View on: PubMed
2003
Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166).
The Journal of pharmacology and experimental therapeutics. 307(1):83-92 [PMID] 12893841.
View on: PubMed
2002
In vitro and in vivo evaluations of dihydroquinoline- and dihydroisoquinoline-based targetor moieties for brain-specific chemical delivery systems.
Journal of drug targeting. 10(1):63-71 [PMID] 11996088.
View on: PubMed
2002
Barriers to remember: brain-targeting chemical delivery systems and Alzheimer’s disease.
Drug discovery today. 7(14):766-74 [PMID] 12547033.
View on: PubMed
2002
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Methods in molecular biology (Clifton, N.J.). 186:301-12 [PMID] 12013781.
View on: PubMed
2002
Synthesis and biological evaluations of brain-targeted chemical delivery systems of [Nva2]-TRH.
The Journal of pharmacy and pharmacology. 54(7):945-50 [PMID] 12162713.
View on: PubMed
2001
Intraocular pressure-lowering activity and in vivo disposition of dipivalyl terbutalone in rabbits.
Drug development and industrial pharmacy. 27(2):137-41 [PMID] 11266225.
View on: PubMed
2001
Design, in vitro stability, and ocular hypotensive activity of t-butalone chemical delivery systems.
Journal of pharmaceutical sciences. 90(8):1026-33 [PMID] 11536206.
View on: PubMed
2000
Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate.
Die Pharmazie. 55(3):206-9 [PMID] 10756542.
View on: PubMed
2000
Recent advances in retrometabolic drug design and targeting approaches.
Die Pharmazie. 55(3):163-6 [PMID] 10756533.
View on: PubMed
2000
Soft drug design: general principles and recent applications.
Medicinal research reviews. 20(1):58-101 [PMID] 10608921.
View on: PubMed
2000
Synthesis and pharmacological evaluation of prodrugs of valproic acid.
Die Pharmazie. 55(3):184-6 [PMID] 10756537.
View on: PubMed
2000
Targeting drugs to the brain by redox chemical delivery systems.
Medicinal research reviews. 20(5):367-416 [PMID] 10934349.
View on: PubMed
1999
Chemical delivery systems: evaluation of physicochemical properties and enzymatic stability of phenylephrone derivatives.
Pharmaceutical development and technology. 4(2):189-98 [PMID] 10231880.
View on: PubMed
1999
Recent advances in retrometabolic design approaches.
Journal of controlled release : official journal of the Controlled Release Society. 62(1-2):209-22 [PMID] 10518653.
View on: PubMed
1997
Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat.
Journal of neurosurgery. 87(5):724-30 [PMID] 9347981.
View on: PubMed
1996
Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 12(2):159-67 [PMID] 8773932.
View on: PubMed
1995
Theoretical studies on the structures of natural and alkylated cyclodextrins.
Journal of pharmaceutical sciences. 84(3):330-6 [PMID] 7616373.
View on: PubMed
1995
Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat.
Journal of pharmaceutical sciences. 84(7):791-3 [PMID] 7562425.
View on: PubMed
1994
In vitro evaluation of a controlled-release site-specific diisovaleryl tert-butalone chemical delivery system for the eye.
Journal of pharmaceutical sciences. 83(3):450-3 [PMID] 8207701.
View on: PubMed
1994
Improved delivery through biological membranes. LXI: Design, synthesis, and evaluation of a lipolol-based intradermal drug targeting system for 5-fluorouracil.
Cancer biotherapy. 9(3):245-52 [PMID] 7820186.
View on: PubMed
1993
Soft drugs 15: mydriatic activity and transcorneal penetration of phenylsuccinic soft analogs of methscopolamine as short acting mydriatics.
Current eye research. 12(6):501-6 [PMID] 8359027.
View on: PubMed
1993
Soft drugs–XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine.
Bioorganic & medicinal chemistry. 1(3):183-7 [PMID] 8081850.
View on: PubMed
1993
Soft drugs–XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine.
Bioorganic & medicinal chemistry. 1(5):327-32 [PMID] 8081862.
View on: PubMed
1993
Soft drugs. 12: Design, syntheses and evaluation of soft anticholinergics.
Drug design and discovery. 10(1):11-21 [PMID] 8399991.
View on: PubMed
1993
Soft drugs. 13: Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics.
Drug design and discovery. 10(1):1-9 [PMID] 8399990.
View on: PubMed
1993
Synthesis and in vitro dopaminergic activity of (2-aminoethyl)-1-hydroxy-2-pyridone type dopamine analogs.
Drug design and discovery. 10(1):35-44 [PMID] 8104516.
View on: PubMed
1991
A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat.
Pharmaceutical research. 8(9):1180-5 [PMID] 1788164.
View on: PubMed
1991
Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse.
Steroids. 56(8):434-9 [PMID] 1788862.
View on: PubMed
1990
A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog.
Pharmaceutical research. 7(8):879-83 [PMID] 2235886.
View on: PubMed
1989
Evidence for prolonged suppression of stress-induced release of adrenocorticotropic hormone and corticosterone with a brain-enhanced dexamethasone-redox delivery system.
Neuroendocrinology. 50(1):9-16 [PMID] 2547177.
View on: PubMed
1989
Improved anticonvulsant activity of phenytoin by a redox brain delivery system I: Synthesis and some properties of the dihydropyridine derivatives.
Journal of pharmaceutical sciences. 78(8):609-16 [PMID] 2778665.
View on: PubMed
1989
Improved anticonvulsant activity of phenytoin by a redox brain delivery system. III: Brain uptake and pharmacological effects.
Journal of pharmaceutical sciences. 78(10):837-43 [PMID] 2600790.
View on: PubMed
1988
A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats.
Life sciences. 42(10):1077-84 [PMID] 3347139.
View on: PubMed

Patents

Issued October 1984
Brain-specific Drug Delivery Dihydropyridine Pyridinium Salt Redox Carrier
#4,479,932
Issued September 1985
Brain-specific Drug Delivery Dihydropyridine And/or Pyridinium Salt Redox Carrier
#4,540,564
Issued October 1986
Method and Compositions for Weight Control Steroids
#4,617,298
Issued November 1986
Testicular-specific Drug Delivery
#4,622,218
Issued February 1988
Brain-specific Dopaminergic Activity Involving Dihydropyridine Carboxamides, Dihydroquinoline and Isoquinoline Carboxamides
#4,727,079
Issued February 1988
Brain-Specific Dopaminergic Activity Involving Dihydropyridine Carboxamides, Dihydroquinoline and Isoquinoline Carboxamides
#4,727,079
Issued September 1988
Brain-Specific Analogues of Centrally Acting Amines
#4,771,059
Issued January 1989
Certain Inositol-nicotinate Ester Derivatives and Polyionic Complexes Therefore Useful for Treating Diabetes Mellitus, Hyperlipidemia and Lactic Acidosis
#4,801,597
Issued April 1989
Brain-specific Drug Delivery Dihydropyridine-pyridinium Salt Redox Carrier
#4,824,850
Issued May 1989
Novel Redox Carriers for Brain-specific Drug Delivery Prodrug for Sustained Release of Dopamine
#4,829,070
Issued September 1989
Method for Treating Male Sexual Dysfunction
#4,863,911
Issued November 1989
Brain-specific Drug Delivery Antiinflammatory Steroids Residue Coupled To a Carrier Comprising a Carbonyl-substituted 1-alkyldihydropyridine Biooxidizable to a Pyridinium Salt
#4,880,921
Issued November 1989
Brain-specific Delivery of Dopamine Utilizing Dihydropyridine/pyridinium Salt-type Redox Carriers
#4,880,816
Issued December 1989
Amino Acids Containing Dihydropyridine Ring Systems for Site-specific Delivery of Peptides to the Brain Dihydropyridine-pyridinium Salt Redox System
#4,888,427
Issued January 1990
Composition and Method for Enhancing Permeability of Topical Drugs Choline Ester and Fatty Acid
#4,892,737
Issued February 1990
Brain-specific Drug Delivery of Steroid Sex Hormones Cleaved from Pyridinium Carboxylates and Dihydro-pyridine Carboxylate Precursors
#4,900,837
Issued June 1990
Brain-specific Analogues of Centrally Acting Amines
#4,933,438
Issued October 1990
Compounds for Site-enhanced Delivery of Radionuclides and Uses Thereof Increased Concentration in Brain; Medical Diagnosis
#4,963,688
Issued October 1990
Novel Radiopharmaceuticals and Chelating Agents Useful in Their Preparation Dihydropyridine-pyridinium Salt Redox System for Drug Delivery in the Brain
#4,963,682
Issued January 1991
Pharmaceutical Formulations for Parenteral Use Decreasing Precipitation At Injection Site or in Lungs or Other Organs by Combining with Hydroxypropyl-beta-cyclodextrin
#4,983,586
Issued March 1991
Improvements in Redox Systems for Brain-targeted Drug Delivery Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug
#5,002,935
Issued April 1991
Brain-specific Drug Delivery Penicillin or Cephalosporin Antibiotics
#5,008,257
Issued May 1991
Labile Derivatives of Ketone Analogs of 3-substituted-1-alkylamino-2-propanols and Their Use as Beta-adrenergic Blockers Treatment of Glaucoma
#5,017,618
Issued May 1991
Redox Systems for Brain-targeted Drug Delivery (CIP)
#5,017,566
Issued June 1991
Pharmaceutical Formulations for Parenteral Use Administering in Aqueous Solution with Cyclodextrin Derivative
#5,024,998
Issued October 1991
NMR-Assayable Ligand-labelled Trifluorothymidine Containing Composition And Method for Diagnosis of HSV Infection
#5,053,215
Issued January 1992
Quarternary Pyridinium Salts to Derivatize Pharmaceutical Peptides for Transport Across the Blood/brain Barrier
#5,079,366
Issued January 1992
Brain-Specific Analogues of Centrally…
#5,082,853
Issued February 1992
Redox Carriers for Brain-specific Drug Delivery Antiviral, Anticancer, Antitumor Agents
#5,087,618
Issued June 1992
Redox Systems for Brain-Targeted Drug Delivery CASE-020
#619788
Issued August 1992
Radiopharmaceuticals and Chelating Agents Useful in Their Preparation Penetration Og Blood Brain Barrier (DIV)
#5,136,038
Issued October 1992
Compounds for Site-enhanced Delivery of Radionuclides Using a Dihydropyridine-pyridinium Salt Type of Redox Delivery; Chelate Compounds; Brain Disorders; Scintigraphy
#5,155,227
Issued January 1993
Targeted Drug Delivery via Phosphonate Derivatives
#5,177,064
Issued February 1993
Brain-specific Drug Delivery Sustained Delivery of Viricides
#5,187,158
Issued June 1993
Anticholinergic Compounds, Composititons and Methods of Treatment Antisecretory Agents, Mydriatics, Antiperspirants
#5,223,528
Issued July 1993
Method of Improving Oral Bioavailability of Carbamazepine Anticonvulsants for Nervous System Disorders
#5,231,089
Issued November 1993
Anticholinergic Compounds, Compositions and Methods of Treatment Antisecretory Agents, Mydriatic Agents and Antiperspirants
#5,258,388
Issued March 1994
Brain-specific Analogues of Centrally Acting Amines Antidepressant
#5,296,483
Issued February 1995
Redox Carriers for Brain-specific Drug Delivery
#5,389,623
Issued May 1995
Targeted Drug Delivery via Phosphonate Derivatives Delivery of Steroid Sex Hormone or Antiinflammatory Steroid to the Brain
#5,413,996
Issued May 1995
Anticholinergic Compounds, Compositions and Methods of Treatment Antiperspirants, Mydriatic
#5,418,244
Issued June 1996
Brain-specific Drug Delivery Analgesic or Narcotic Antagonist (DIV)
#5,525,727
Issued March 1997
Anticholinergic Compounds, Compositions and Methods of Treatment Mydriatics, Antiperspirants
#5,610,188
Issued April 1997
Targeted Drug Delivery via Phosphonate Derivatives to Brain
#5,618,803
Issued April 1997
Anticholinergic Compounds, Compositions and Methods of Treatment
#5,618,826
Issued April 1997
Brain-enhanced Delivery of Neuroactive Peptides by Sequential Metabolism
#5,624,894
Issued June 1997
Anticholinergic Compounds, Compositions and Methods of Treatment Antiperspirant, Mydriatic, Antisecretory Agents
#5,637,601
Issued June 1997
Redox Amino Acids and Peptides Containing Them Sustained Delivery of Pharmacologically Active Peptides to Brain
#5,639,885
Issued April 1999
Molecular Size-Based Approach to Estimate LOGP
#TX-916-774
Issued April 1999
Computer-Aided Retrometabolic Drug Design
#TX-916-779
Issued August 2002
Compounds and Method For The Prevention and Treatment of Diabetic Retinopathy
#6,440,933
Issued September 2005
Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy (DIV)
#6,943,145
Issued October 2006
Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy (CON)
#7,115,566

Contact Details

Emails:
Business:
bodor@cop.ufl.edu